<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044625</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingCYH-ICU-007</org_study_id>
    <nct_id>NCT04044625</nct_id>
  </id_info>
  <brief_title>Effects of High-intensity Noninvasive Positive Pressure Ventilation in AECOPD</brief_title>
  <official_title>Effects of High-intensity Versus Low-intensity Noninvasive Positive Pressure Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effects of high-intensity noninvasive positive pressure&#xD;
      ventilation (NPPV), as compared with low-intensity NPPV, on hypercapnia, consciousness,&#xD;
      inspiratory muscle effort, dyspnea, NPPV tolerance, inflammatory response, adverse events and&#xD;
      other outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Actual">March 29, 2021</completion_date>
  <primary_completion_date type="Actual">March 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaCO2 measured at 24 hours after enrollment</measure>
    <time_frame>24 hours</time_frame>
    <description>PaCO2 measured at 24 hours after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PaCO2 measured at 2 hours after enrollment</measure>
    <time_frame>2 hours</time_frame>
    <description>PaCO2 measured at 2 hours after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaCO2 measured at 6 hours after enrollment</measure>
    <time_frame>6 hours</time_frame>
    <description>PaCO2 measured at 6 hours after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaCO2 measured at 48 hours after enrollment</measure>
    <time_frame>48 hours</time_frame>
    <description>PaCO2 measured at 48 hours after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaCO2 measured at 72 hours after enrollment</measure>
    <time_frame>72 hours</time_frame>
    <description>PaCO2 measured at 72 hours after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow coma scale score</measure>
    <time_frame>72 hours</time_frame>
    <description>The glasgow coma scale score, ranging from 3 (coma) to 15 (normal consciousness), will be used to assess the consciousness level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ΔPes</measure>
    <time_frame>72 hours</time_frame>
    <description>Inspiratory esophageal pressure swing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score</measure>
    <time_frame>72 hours</time_frame>
    <description>The dyspnea score will be assessed using a verbal analogue scale with levels from 0 (no dyspnea) to 10 (maximum dyspnea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPPV tolerance score</measure>
    <time_frame>72 hours</time_frame>
    <description>NPPV tolerance will be recorded on a 4-point scale and then dichotomized into acceptable (score of 2 or 3) or poor (score of 0 or 1) tolerance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of TNF-α</measure>
    <time_frame>72 hours</time_frame>
    <description>Plasma level of TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of I-1β</measure>
    <time_frame>72 hours</time_frame>
    <description>Plasma level of IL-1β</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of IL-6</measure>
    <time_frame>72 hours</time_frame>
    <description>Plasma level of IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of IL-8</measure>
    <time_frame>72 hours</time_frame>
    <description>Plasma level of IL-8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of IL-10</measure>
    <time_frame>72 hours</time_frame>
    <description>Plasma level of IL-10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Acute Exacerbation of Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>High-intensity NPPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive high-intensity noninvasive positive pressure ventilation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-intensity NPPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will receive low-intensity noninvasive positive pressure ventilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-intensity NPPV</intervention_name>
    <description>In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.</description>
    <arm_group_label>High-intensity NPPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low-intensity NPPV</intervention_name>
    <description>In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.</description>
    <arm_group_label>Low-intensity NPPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of COPD according to the criteria of the Global Initiative for Chronic&#xD;
             Obstructive Lung Disease in 2019&#xD;
&#xD;
          2. Presence of acute exacerbation&#xD;
&#xD;
          3. Arterial pH &lt;7.35 with arterial carbon dioxide tension (PaCO2) &gt;45 mmHg on room air or&#xD;
             supplemental oxygen&#xD;
&#xD;
          4. PaCO2 &gt;45 mmHg following low-intensity NPPV of ≥6 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years&#xD;
&#xD;
          2. Excessive amount of respiratory secretions or weak cough&#xD;
&#xD;
          3. Upper airway obstruction&#xD;
&#xD;
          4. Recent oral, facial, or cranial trauma or surgery; recent gastric or esophageal&#xD;
             surgery&#xD;
&#xD;
          5. Potential risk factors for restrictive ventilatory dysfunction (eg, consolidation or&#xD;
             removal of at least one pulmonary lobe, massive pleural effusion, chest wall&#xD;
             deformity, continuous strapping with thoracic or abdominal bandage, and severe&#xD;
             abdominal distention)&#xD;
&#xD;
          6. Active upper gastrointestinal bleeding&#xD;
&#xD;
          7. Cardiac or respiratory arrest&#xD;
&#xD;
          8. Arterial oxygen tension/fraction of inspired oxygen &lt;100 mmHg&#xD;
&#xD;
          9. Pneumothorax&#xD;
&#xD;
         10. Severe ventricular arrhythmia or myocardial ischemia&#xD;
&#xD;
         11. Severe hemodynamic instability despite fluid repletion and use of vasoactive agents&#xD;
&#xD;
         12. Severe metabolic acidosis&#xD;
&#xD;
         13. Refusal to receive NPPV&#xD;
&#xD;
         14. Endotracheal intubation already performed before ICU admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zujin Luo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Zujin Luo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

